Testing Markers for Neuropsychiatric Disorders

PANS and PANDAS Research at Moleculera Labs

In the scientific and medical literature there are well-established links between inflammation and psychological disturbances. Various studies have shown that markers of inflammation are associated with increased incidence of neurologic symptoms. Inflammation is a normal part of the immune system response.

We are researching an association between autoantibodies against other neuronal antigens, and the clinical diagnosis of neuropsychiatric disorders such as chronic depression, bipolar disorder and schizophrenia. We are examining a number of candidate neuronal targets that have a known biological impact on normal neuronal functions. Our goal is to develop additional testing panels that would identify if patients suffering from other neuropsychiatric conditions may be responsive to autoimmune therapy rather than treatment with neuropsychiatric drugs. Should we find value and strong clinical evidence of neuropsychiatric associations with any of these new targets, we will complete the clinical validation and regulatory requirements necessary to make these available for physicians in the future.

“Big Data” Project

We are working on an expansive project to collect large amounts of information from those patients who have given us Informed Consent when they have sent in their specimen for testing with the Cunningham Panel™. Questionnaires will be electronically sent to parents of patients and this information will be kept strictly confidential. The cumulative information will be used to examine clusters of data in association with laboratory results, medical treatments and resulting patient outcomes. The compilation of this data is anticipated to provide hierarchical clustering information and algorithms that would assist physicians in predicting treatment outcomes and assist in their treatment decisions. Once we complete this project and have thoroughly tested these algorithms and find reproducible evidence of their value, we will make these algorithms available to physicians.